Single-donor (Apheresis) platelets and pooled whole-blood-derived platelets - Significance and assessment of both blood products

Clinical Laboratory

Volumn 60, Issue 4, 2014, Pages

  Hitzler, Walter E ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; THROMBOCYTE CONCENTRATE;

APHERESIS PLATELET CONCENTRATE; BLOOD DONOR; BLOOD SAFETY; COMPARATIVE EFFECTIVENESS; DISEASE COURSE; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; GOLD STANDARD; HEMATOLOGICAL PARAMETERS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HOSPITAL PHYSICIAN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; POPULATION DENSITY; REVIEW; RISK FACTOR; THERAPY EFFECT; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; WHOLE BLOOD DERIVED PLATELET CONCENTRATE; APHERESIS; PATIENT SAFETY; RISK ASSESSMENT; THROMBOCYTE;

BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; HUMANS; PATIENT SAFETY; PLATELET TRANSFUSION; RISK ASSESSMENT;

EID: 84898874974     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2014.140210     Document Type: Review

References (88)

1. Anderson NA, Gray S, Copplestone JA, Chan DC, Hamon M, Prentice AG, Johnson SA, Phillips M, van Waeg G, Oakhill A, Abeyasekera S, Pamphilon DH. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfus Med 1997;7:33-9.
2. Bender AW, Zimmermann R. Vergütung von Apherese- Thrombozytenkonzentraten. Entscheidungsaufbereitung und Anmerkung. MedR 2010;28:524-7.
3. Bender AW, Zimmermann R. Einsatz von Apherese-Thrombozytenkonzentraten und deren Vergütung im DRG-System. MedR 2013;31:237-242.
4. Bundesärztekammer. Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten - Gesamtnovelle 2008. Deutscher Ärzteverlag, Köln, 2008.
5. Bundesärztekammer und Paul-Ehrlich-Institut. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Deutscher Ärzteverlag, Köln, 2010.
6. Eder AF, Dy BA, Kennedy JM, Notari Iv EP, Strupp A, Wissel ME, Reddy R, Gibble J, Haimowitz MD, Newman BH, Chambers LA, Hillyer CD, Benjamin RJ. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008;48:1809-19.
7. Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008;48:1447-58.
8. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, Brandwein JM, Szczepiorkowski ZM, AuBuchon JP, Barty RL, Lee KA; SToP Study Investigators of the BEST Collaborative. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009;113:1564-73.
9. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ. Clinical effecttiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010;150:209-17.
10. Klüter H, Dörges L, Maass E, Wagner T, Bartels H, Kirchner H. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. Ann Hematol 1996;73:85-9.
11. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivtion: the SPRINT Trial. Blood 2004;104:1534-41.
12. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50:2362-75.
13. Slichter SJ. Eliminate prophylactic platelet transfusions? N Engl J Med 2013; 368: 1837-8.
14. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gemsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600-13.
15. Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, Bakrania L, Llewelyn C, Littlewood T, Soutar R, Norfolk D, Copplestone A, Smith N, Kerr P, Jones G, Raj K, Westerman DA, Szer J, Jackson N, Bardy PG, Plews D, Lyons S, Bielby L, Wood EM, Murphy MF; TOPPS Investigators. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013;368:1771-80.
16. Strindberg J, Berlin G. Transfusion of platelet concentrates - clinical evaluation of two preparations. Eur J Haematol 1996;57: 307-11.
17. Vamvakas EC. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009;49:2743-58.
18. Vamvakas EC. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets. Clin Lab 2010;56:263-79.
19. Vamvakas EC. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011;51:1058-71.
20. Vamvakas EC, Hitzler WE. Consistency and proportionality in policy decision-making in blood safety: the case for an all-apheresis platelet supply in Germany. Clin Lab 2013;59:1-22.
21. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L; euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
22. Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dölken G, Klenner A, Hänel M, Herbst R, Junghanss C, Ehninger G; Study Alliance Leukemia. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012;380:1309-16.
23. Weber CF, Meininger D, Byhahn C, Seifried E, Zacharowski K, Adam E, Henschler R, MOller MM. Konventionelle vs. Pathogen-inaktivierte Thrombozytenkonzentrate bei perioperativer Koagulopathie. Eine prospektive Kohortenstudie. Chirurg 2011; 82:348-58. Weber CF, Meininger D, Byhahn C, Seifried E, Zacharowski K, Adam E, Henschler R, Müller MM. Konventionelle vs. Pathogen-inaktivierte Thrombozytenkonzentrate bei perioperativer Koagulopathie. Eine prospektive Kohortenstudie. Chirurg 2011;82:348-58.
24. Zimmermann R, Bender AW. Pool- versus Apherese-Thrombozytenkonzentrate. Wissenschaftliches Gutachten zur Wertigkeit der Präparate und den rechtlichen lmplikationen. Auftraggeber: Berufsverband der Deutschen Transfusionsmediziner e.V. (BDT), Köln, erstellt zum 07.10.2011, veröffentlicht vom BDT am 05.11.2011. Link: http://www.bdtev.de/wp-content/ uploads/2011/05/BDT-Gutachten-ATK-vs-PTK-20111007-Zimmermann-Bender.pdf
25. Carmen Hurtado, Santiago Bonanad, Ma Angeles Soler, Vicente Mirabet, Ignacio Blasco, Ma Dolores Planelles, Alicia De Miguel. Quality analysis of blood components obtained by automated buffy-coat layer removal with a Top & Bottom system (Optipress ®II). Haematologica 2000;85:390-395.
26. Oei W, Janssen MP, van der Poel CL, van Steenbergen JE, Rehmet S, Kretzschmar ME. Modeling the transmission risk of emerging infectious diseases through blood transfusion. Transfusion. 2013 Jul;53(7):142l-8. doi: 10.1111/j.1537-2995.2012.03941.x. Epub 2012 Nov 1.
27. Stanworth SJ, Hyde C, Brunskill S, Murphy MF. Platelet transfusion prophylaxis for patients with hematological malignancies: Where to now? Br J Haematol 2005;131:588-95.
28. Estcourt L, Stanworth S, Doree C, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with hematological disorders after chemotherapy and stem-cell transplantation. Cochrane Datab System Rev 2012:CD004259.
29. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997;337:1870-5.
30. Stanworth SJ, Dyer C, Choo L, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (Trial of Platelet Prophylaxis) to assess the effecttiveness of prophylactic platelet transfusions. Transfus Med Rev 2010;24:163-71.
31. Department of Health and Human Services. The 2007 National Blood Collection and Utilization Survey Report. Washington, DC:DHHS, 2008.
32. Vamvakas EC. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice. Transfusion 2012; DOI 10.1111/j.1537-2995.2012.03825.x
33. Collinge J, Whitfield J, McKintosh E, et al. Kuru in the 21st century - an acquired human prion disease with very long in Vamvakas EC. Establishing causation in transfusion medicine and related tribulations. Transfus Med Rev 2011;25:81-8.
34. cubation periods. Lancet 2006;367:2068-74.
35. Bugert P, Dugrillon A, Gunaydin A, Eichler H, Kluter H. Messenger RNA profiling of human platelets by microarray hybriddization. Thromb Haemost 2003;90:738-48.
36. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003; 101:2285-93.
37. Rowley JW, Oler A, Tolley ND, et al. Genomewide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011;118:e101-11.
38. Tsao CH. Rough endoplasmic reticulum and ribosomes in blood platelets. Scand J Haematol 1971;8:134-40.
39. Kieffer N, Guichard J, Farcet JP, Vainchenker W, Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987;164:189-95.
40. Booyse FM, Rafelson ME, Jr. Studies on human platelets. I. Synthesis of platelet protein in a cell-free system. Biochim Biophys Acta 1968;166:689-97.
41. Weyrich AS, Dixon DA, Pabla R, et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci U S A 1998;95:5556-61.
42. Evangelista V, Manarini S, Di Santo A, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006;98:593-5.
43. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009;16:961-6.
44. Edelstein LC, Bray PF. MicroRNAs in platelet production and activation. Blood 2011;117:5289-96.
45. Bruchova H, Merkerova M, Prchal JT. Aberrant expression of microRNA in polycythemia vera. Haematologica 2008;93:1009-16.
46. Nagalla S, Shaw C, Kong X, et al. Platelet microRNA-mRNA co-expression profiles correlate with platelet reactivity. Blood 2011; 117:5189-97.
47. Osman A, Falker K. Characterization of human platelet micro-RNA by quantitative PCR coupled with an annotation network for predicted target genes. Platelets 2011;22:433-41.
48. Kondkar AA, Bray MS, Leal SM, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010;8:369-78.
49. Hitzler W, Vamvakas EC. Platelet microRNA profiles and the effect of pathogen reduction on platelet function. Clin Lab 2011;57: 451-4.
50. Vamvakas EC. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012;102:302-16.
51. https://login.medscape.com/login/sso/getlogin?urlCache= aHR0cDovL3d3dy5tZWRzY2FwZS5jb20vdmlld2FydGljbGUvNzc1OT13&ac=401
52. Ringwald J, Zimmermann R, Eckstein R. The new generation of platelet additive solution for storage at 22°C: development and current experience.Transfus Med Rev 2006; 20: 158-64.
53. Schrezenmeier H, Seiffied E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010;99:1-15.
54. Hardwick J. Blood processing. Vox Sang ISBT Science Series 2008;3:148B76.
55. Wilsher C, Garwood M, Sutherland J, Turner C, Cardigan R. The effect of storing whole blood at 22 degrees C for up to 24 hours with and without rapid cooling on the quality of red cell concentrates and fresh-frozen plasma. Transfusion 2008;48:2338-47.
56. Offergeld R, Ritter S, Kamp C, et al. Differences in infection risks between pool and apheresis platelets - a mathematic model. Transfus Med Hemother 2012;39(suppl 1):1-66. Abstract # P3.02.
57. OLG Koblenz, Urteil vom 20.06.2012, 5 U 1450/11
58. Stellungnahme des Paul-Ehrlich-Instituts (PEI) zur Sicherheit von Pool-Thrombozytenkonzentraten (PTK) und Apherese-Thrombozytenkonzentraten (ATK) (German). Paul-Ehrlich-Institut (PEI) 29.11.2011 und 06.11.2012. Available at: http://www.pei.de/DE/arzneimittelsicherheit-vigilanz/ archivsicherheitsinformationen/2011/ablage2011/2011-11-29-haemovigilanz- stellungnahmesicherheit-ptk-atk.html
59. Funk MB, et al. Hämovigilanz-Bericht des Paul-Ehrlich-Instituts 2010: Auswertung der Meldungen von schwerwiegenden Transfusionsreaktionen nach § 63c AMG ,2012 (German). Available at: http://www.pei.de/ haemovigilanzbericht
60. Kamel H, Tomasulo P, Bravo M, et al. Delayed adverse reactions to blood donation. Transfusion 2010;50:556-65.
61. Greinacher A, Fendrich K, Brzenska R, et al. Implications of demographics on future blood supply: A population-based cross-sectional study. Transfusion 2011;51:702-9.
62. Winters JL. Complications of donor apheresis. J Clin Apher 2006;21:132-41.
63. Stohlawetz P, Stiegler G, Jilma B, et al. Measurement of the levels of reticulated platelets after plateletpheresis to monitor actively of thrombopoiesis. Transfusion 1998;38:454-8.
64. Lazarus EF, Browning J, Norman J, et al. Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. Transfusion 2001;41:756-61.
65. Amrein K, Katsching C, Sipurzynski S, et al. Apheresis affects bone and mineral metabolism. Bone 2010;46:789-95.
66. Vamvakas EC, Hitzler WE. Interventions to Reduce Platelet Prophylactic Transfusions in Patients with Hypoproliferative Thrombocytopenia: Providing Patients with the Full Benefit. Clin Lab 2013;59:459-464.
67. Vamvakas EC. The ethics of wasting the donor's gift of buffy coat. Vox Sang 2011;100:256-7.
68. Stein J, Besley J, Brook C, Hamill M, Klein E, Krewski D, Murphy G, Richardson M, Sima J, Skinner M, Steiner R, van Aken P & Devine D. Risk-based decision-making for blood safety: preliminary report of a consensus conference. Vox Sanguinis (2011) 101,277-281.
69. Bennett JL, Blajchman MA, Delage G, Fearon M, and Devine D. Proceedings of a Consensus Conference: Risk-Based Decision Making for Blood Safety Transfusion Medicine Reviews, Vol 25, No 4 (October), 2011: pp 267-292.
70. Kleinman S, Cameron C, Custer B, Busch M, Katz L, Kralj B, Matheson I, Murphy K, Preiksaitis J, and Devine D. Modeling the risk of an emerging pathogen entering the Canadian blood supply. TRANSFUSION Volume 50, December 2010.
71. Watkins NA, Dobra S, Bennett P, Cairns J, and Turner ML. The Management of Blood Safety in the Presence of Uncertain Risk: A United Kingdom Perspective. Transfusion Medicine Reviews, Vol 26, No 3 (July), 2012: pp 238-251.
72. Dietz K, Raddatz G, Wallis J, Müller N, Zerr I, Duerr HP, Lefèvre H, Seifried E, and Löwer J. Blood Transfusion and Spread of Variant Creutzfeldt-Jakob Disease. Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 1, January 2007.
73. Yasui Y, Yanai H, Sawanpanyalert P, Tanaka H. A statistical method for the estimation of window-period risk of transfusion-transmitted HIV in donor screening under non-steady state. Biostatistics (2002), 3, 1, pp. 133-143.
74. Ritter S, Hamouda O, Offergeld R. Demografie und Spendeaktivität von Blut- und Plasmaspendern in Deutschland Update 2010 und 5-Jahres-Vergleich. Bundesgesundheitsblatt 2012,55:914-922,DOI 10.1007/s00103-012-1515-2.
75. Henseler O, Heiden M, Haschberger B, Hesse J, Seitz R. Bericht zur Meldung nach § 21 TFG für die Jahre 2010 und 2011. Bundesgesundheitsblatt 2013, 56:1352-1367,DOI 10.1007/s00103013-1802-6.
76. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, Penney M, Hegazy D and Ironside JW. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004;203:733-739.
77. Frosh A, Smith LC, Jackson CJ, Linehan JM, Brandner S, Wadsworth JDF, Collinge J. Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein Lancet 2004; 364:1260-62.
78. Gill ON, Spencer Y, Richard-Loendt A, Kelly C, Dabaghian R, Boyes L, Linehan J, Simmons M, Webb P, Bellerby P, Andrews N, Hilton DA, Ironside JW, Beck J.Poulter M, Mead S, Brandner S. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 2013;347:f5675 doi: 10.1136/bmj.f5675 (Published 15 October 2013).
79. Clewley JP, Kelly CM, Andrews N, Vogliqi K, Mallinson G, Kaisar M, Hilton DA, Ironside JW, Edwards P, McCardle L, Ritchie DL, Dabaghian R, Ambrose HE, Gill ON. Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. BMJ 2009;338:b1442 doi: 10.1136/bmj.b1442.
80. Douet JY, Zafar S, Perret-Liaudet A, Lacroux C, Lugan S, Aron N, Cassard H, Ponto C, Corbier̀e F, Torres JM, Zerr I, Andreoletti O. Detection of Infectivity in Blood of Persons with Variant and Sporadic Creutzfeldt-Jakob Disease. Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 20, No. 1, January 2014.
81. Martin M, Legras JF, Pouchol E, Trouvin JH. Évaluation du risque transfusionnel vis-à-vis de la variante de la maladie de Creutzfeldt-Jakob en France Transfusion risk analysis with regard to vCJD in France. Transfusion Clinique et Biologique 13 (2006) 298-303.
82. Lefrère JJ. Le risque de contamination par le prion lors de la transfusion de produits sanguins labiles. The risk of prion contamination through the transfusion of cellular products. Transfusion Clinique et Biologique 14 (2007) 25-34.
83. Ironside JW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapies. Haemophilia (2006), 12, (Suppl. 1), 8-15.
84. McCutcheon S, Blanco ARA, Houston EF, Wolf C, Tan BCh, Smith A, Groschup MH, Hunter N, Hornsey VS, MacGregor IR, Prowse CV, Turner M, Manson JC. All Clinically-Relevant Blood Components Transmit Prion Disease following a Single Blood Transfusion: A Sheep Model of vCJD. PLoS ONE 6(8): e23169. doi: 10.1371/journal.pone.0023169
85. Leffère JJand Hewitt P. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France. Transfusion 2009;49:797-812.
86. Llewelyn CA, Hewitt PE, Knight RSG, Amar K, Cousens S, Mackenzie J, Will RG. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417-21.
87. Dobra SA, Bennett PG. vCJD and blood transfusion: risk assessment in the United Kingdom Variant de la maladie de Creutzfeld-Jakob et transfusion sanguine: estimation du risque au Royaume-Uni. Transfusion Clinique et Biologique 13 (2006) 307-311.
88. Vamvakas EC. Decision making in transfusion medicine. ISBN 978-1-56395-828-1. AABB Press 2011.